表紙
市場調查報告書

全球主要25個疫苗市場預測(∼2029年)

Top 25 Vaccines Market Forecast to 2029: Prevnar, Gardasil, Fluzone/Vaxigrip, Pentacel, Infanrix, Pediarix, GSK Hepatitis Vaccine, Pneumovax 23, Varivax, Bexsero, Boostrix, Menactra, RotaTeq, Rotarix, Zostavax, Synflorix, FluLaval/Fluarix, Others

出版商 Visiongain Ltd 商品編碼 933207
出版日期 內容資訊 英文 190 Pages
商品交期: 最快1-2個工作天內
價格
全球主要25個疫苗市場預測(∼2029年) Top 25 Vaccines Market Forecast to 2029: Prevnar, Gardasil, Fluzone/Vaxigrip, Pentacel, Infanrix, Pediarix, GSK Hepatitis Vaccine, Pneumovax 23, Varivax, Bexsero, Boostrix, Menactra, RotaTeq, Rotarix, Zostavax, Synflorix, FluLaval/Fluarix, Others
出版日期: 2020年02月27日內容資訊: 英文 190 Pages
簡介

全球疫苗市場預測將從2018年的251億9,000萬美元以8.42%的年複合成長率擴大,2024年成為408億美元的規模。在已開發國家中需求持續擴大。這個主要理由因為是在低所得∼中所得的國家中疫苗的需求高漲。

本報告提供全球疫苗市場相關調查,市場概要和各市場區隔趨勢,各地區趨勢,及參與企業的簡介相關資訊彙整。

第1章 報告概要

第2章 全球人疫苗市場簡介

  • 人類疫苗:以世界的疾病預防作為目的
  • 所謂社會、經濟負擔
  • 疫苗技術
  • 主要的25個疫苗市場上的影響者
    • 政府和國際組織
    • 主要製造商

第3章 市場預測

第4章 全球市場:產業趨勢

第5章 主要疫苗:收益預測(2019∼2029年)

第6章 主要已開發國家疫苗市場

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第7章 主要製造商

  • GlaxoSmithKline (GSK)
  • Merck& Co.
  • Sanofi
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca
  • Eli Lilly and Company
  • 武田藥品工業株式會社
  • Serum Institute of India Private Limited
  • Emergent BioSolutions Inc.

第8章 研究開發

  • 預防疫苗研究開發平台
  • 治療疫苗研究開發平台

第9章 全球疫苗市場定性分析

第10章 結論

附錄

目錄
Product Code: PHA0440

Title:
Top 25 Vaccines Market Forecast to 2029:
Prevnar/Prevnar 13, Gardasil/Gardasil 9, Fluzone/Vaxigrip, Pentacel, Infanrix, Pediarix, GSK Hepatitis Vaccine, Pneumovax 23, Varivax, Bexsero, Boostrix, Menactra, RotaTeq, Rotarix, Zostavax, Synflorix, FluLaval/Fluarix, ProQuad, M-M-R II, Adacel, Menveo, Repevax, Cervarix, FSME/IMMUN-TicoVac, Ixiaro, FluMist/Fluenz.

Visiongain expects market growth from $25.19bn in 2018 to $40.80bn in 2024, growing at a CAGR of 8.42%. The developing markets will continue to grow demand; this is mainly due to the great need for vaccines in low-income and middle-income countries.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 190-page report you will receive 53 tables and 59 figures - all unavailable elsewhere.

The 190-page report provides clear detailed insight into the top 25 vaccines market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Top 25 Vaccines Market revenue forecasts from 2019-2029:

  • Adacel
  • Bexsero
  • Boostrix
  • Cervarix
  • FluLaval / Fluarix
  • FluMist/Fluenz
  • Fluzone/Vaxigrip
  • FSME/IMMUN-TicoVac
  • Gardasil/Gardasil 9
  • Hepatitis Vaccines (GSK)
  • Infanrix/Pediarix
  • Ixiaro
  • Menactra
  • Menveo
  • M-M-R II
  • Pentacel
  • Pneumovax 23
  • Prevnar/Prevnar 13
  • ProQuad
  • Repevax
  • Rotarix
  • RotaTeq
  • Synflorix
  • Varivax
  • Zostavax

Top 25 Vaccines Market revenue forecasts from 2019-2029 by Regional and National Market:

  • US
  • Canada
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Japan
  • China
  • India
  • Brazil
  • Mexico
  • Russia
  • South Africa
  • RoW

The forecast for each regional market is further segmented by leading vaccines.

Profiles of the selected leading companies:

  • AstraZeneca
  • Eli Lilly
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer
  • Sanofi
  • Serum Institute of India Private Limited
  • Takeda

Discussion on Research & Development:

  • Prophylactic Vaccines: Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines
  • Therapeutic Vaccines

Qualitative analysis of the generic drugs market:

  • SWOT Analysis of the vaccines market
  • STEP Analysis of the vaccines market
  • Discussion on factors that drive and restrain the vaccines market

Key Questions Answered by This Report:

  • What is the current size of the overall global human vaccines market? How much will this market be worth from 2018 to 2029?
  • What are the main drivers and restraints that will shape the overall vaccines market over the next ten years?
  • What factors will affect that industry and market over the next ten years?
  • What are the largest national markets for the world vaccines? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2029?
  • How will political and regulatory forces influence regional markets?
  • How will market shares of the leading national markets change by 2029, and which geographical region will lead the market in 2029?
  • Who are the leading companies and what are their activities, results, developments and prospects?
  • What are the leading vaccines? What are their revenues and latest developments?
  • What are some of the most prominent human vaccines currently in development?
  • What are the main trends that will affect the world vaccines market between 2018 and 2029?
  • What are the main strengths, weaknesses, opportunities and threats for the market?
  • What are the social, technological, economic and political influences that will shape that industry over the next ten years?
  • How will the Global Top 25 Vaccines Market evolve over the forecast period, 2018 to 2029?

Visiongain's study is intended for anyone requiring commercial analyses for the Top 25 Vaccines Market. You find data, trends and predictions.

Buy our report today Top 25 Vaccines Market Forecast 2019-2029: Prevnar/Prevnar 13; Gardasil/Gardasil 9; Fluzone/Vaxigrip; Pentacel; Infanrix, Pediarix; GSK Hepatitis Vaccine; Pneumovax 23; Varivax; Bexsero; Boostrix; Menactra; RotaTeq; Rotarix; Zostavax; Synflorix; FluLaval/Fluarix; ProQuad; M-M-R II; Adacel; Menveo; Repevax; Cervarix; FSME/IMMUN-TicoVac; Ixiaro; FluMist/Fluenz.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Vaccines Market
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analytical Study
  • 1.5 Who is This Report For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Introduction to the World Human Vaccines Market

  • 2.1 Human Vaccines - Aiming for Global Disease Prevention
  • 2.2 What is the Social and Economic Burden?
  • 2.3 Vaccine Technology
    • 2.3.1 Inactivated Vaccines
    • 2.3.2 Live Attenuated Vaccines
    • 2.3.3 Conjugate Vaccines
    • 2.3.4 Recombinant Vector Vaccines
  • 2.4 Key Influencers of the Human Top 25 Vaccines Market
    • 2.4.1 Governments and International Organizations
      • 2.4.1.1 The World Health Organisation (WHO)
      • 2.4.1.2 The Governmental Influence
    • 2.4.2 Leading Manufacturers
      • 2.4.2.1 Merck & Co.
      • 2.4.2.2 Sanofi
      • 2.4.2.3 GlaxoSmithKline
      • 2.4.2.4 Pfizer

3. Global Top 25 Vaccines Market Outlook, 2019-2029

  • 3.1 Global Top 25 Vaccines Market Forecast, 2019-2029

4. The World Top 25 Vaccines Market: Industry Trends, 2019-2029

  • 4.1 Undulating Demand
  • 4.2 Supply Restraints
  • 4.3 Funding Trends
  • 4.4 Protecting the Workforce of an Economy

5. Leading Vaccines: Revenue Forecasts, 2019-2029

  • 5.1 Prevnar/Prevnar 13 (Pfizer) - Pneumococcal Pneumonia
  • 5.2 Gardasil/Gardasil 9 (Merck & Co.) - HPV
  • 5.3 Fluzone/Vaxigrip (Sanofi) - Influenza
  • 5.4 Pentacel (Sanofi) - DtaP, Polio, HiB
  • 5.5 ProQuad (Merck) - Varicella, Measles, Mumps, & Rubella
  • 5.6 Infanrix/Pediarix (GSK) - Diptheria, Tetanus and Acellular Pertussis
  • 5.7 Zostavax (Merck and Co.) - Herpes
  • 5.8 RotaTeq (Merck and Co.) - Rotavirus
  • 5.9 Hepatitis Vaccines (GSK) - Hepatitis A & B
  • 5.10 Menactra (Sanofi) - Meningococcal
  • 5.11 Pneumovax 23 (Merck) - Pneumococcal Disease
  • 5.12 Varivax (Merck and Co.) - Chickenpox
  • 5.13 Bexsero (GSK) - Tetanus, Diphtheria, & Pertussis
  • 5.14 Boostrix (GSK) - Meningitis
  • 5.15 FluMist/Fluenz (AstraZeneca)- Influenza Infection
  • 5.16 Rotarix (GSK) - Rotavirus Gastroenteritis
  • 5.17 Synflorix (GSK) - Meningitis, Blood Infection, Pneumonia
  • 5.18 FluLaval / Fluarix (GSK) - Seasonal Influenza Prophylaxis
  • 5.19 M-M-R II (Merck) - Measles, Mumps, & Rubella
  • 5.20 Adacel (Sanofi) - Tetanus, Diphtheria, & Pertussis
  • 5.21 Menveo (GSK) - Meningitis
  • 5.22 Repevax (Sanofi) - Diphtheria, Tetanus, Pertussis, & Poliomyelitis
  • 5.23 Cervarix (GSK) - Human Papilloma Virus Infection
  • 5.24 FSME/IMMUN-TicoVac (Pfizer) - Tick-Borne Encephalitis
  • 5.25 Ixiaro (Valneva) - Encephalitis

6. Regional and Leading Developed National Vaccines Markets, 2018-2029

  • 6.1 North America Top 25 Vaccines Market, 2018-2029
    • 6.1.1 US Top 25 Vaccines Market, 2018
    • 6.1.2 Canada Top 25 Vaccines Market, 2018
  • 6.2 Europe Top 25 Vaccines Market, 2018-2029
    • 6.2.1 German Top 25 Vaccines Market, 2018 - 2029
    • 6.2.2 UK Top 25 Vaccines Market, 2018-2029
    • 6.2.3 French Top 25 Vaccines Market, 2018-2029
    • 6.2.4 Italian Top 25 Vaccines Market, 2018-2029
    • 6.2.5 Spanish Top 25 Vaccines Market, 2018-2029
  • 6.3 Asia-Pacific Top 25 Vaccines Market, 2018-2029
    • 6.3.1 Japanese Top 25 Vaccines Market, 2018-2029
    • 6.3.2 Chinese Top 25 Vaccines Market, 2018-2029
    • 6.3.3 Indian Top 25 Vaccines Market, 2018-2029
  • 6.4 RoW Top 25 Vaccines Market, 2018-2029
    • 6.4.1 Brazilian Top 25 Vaccines Market, 2018-2029
    • 6.4.2 Russian Top 25 Vaccines Market, 2018-2029
    • 6.4.3 Mexican Top 25 Vaccines Market, 2018-2029
    • 6.4.4 South Africa Top 25 Vaccines Market, 2018-2029

7. Leading Manufacturers of Vaccines for Human Use

  • 7.1 GlaxoSmithKline (GSK)
    • 7.1.1 GSK Vaccine Performance
    • 7.1.2 GSK Developments
      • 7.1.2.1 Mergers and Acquisitions
      • 7.1.2.2 GSK Vaccine Pipeline
  • 7.2 Merck& Co.
    • 7.2.1 Merck Vaccine Performance
    • 7.2.2 Merck Developments
      • 7.2.2.1 Merck Market Movements
      • 7.2.2.2 Collaborations
      • 7.2.2.3 Merck Pipeline
  • 7.3 Sanofi
    • 7.3.1 Sanofi Vaccine Performance
    • 7.3.2 Sanofi Developments
      • 7.3.2.1 Acquisitions & Expansions
      • 7.3.2.2 Sanofi Vaccine Pipeline
  • 7.4 Pfizer
    • 7.4.1 Pfizer Vaccine Performance
    • 7.4.2 Pfizer Developments
      • 7.4.2.1 Pfizer Mergers & Acquisitions
      • 7.4.2.2 Pfizer Pipeline
  • 7.5 Johnson & Johnson
    • 7.5.1 Financial Overview
  • 7.6 AstraZeneca
    • 7.6.1 Financial Overview
  • 7.7 Eli Lilly and Company
    • 7.7.1 Eli Lilly and Company Vaccine Performance
    • 7.7.2 Eli Lilly and Company Developments
  • 7.8 Takeda Pharmaceutical Company Limited
    • 7.8.1 Takeda Pharmaceutical Company Limited Vaccine Performance
    • 7.8.2 Financial Overview
  • 7.9 Serum Institute of India Private Limited
    • 7.9.1 Serum Institute of India Private Limited Vaccine Performance
  • 7.10 Emergent BioSolutions Inc.
    • 7.10.1 Emergent BioSolutions Inc.Vaccine Performance
    • 7.10.2 Key Strategic Acquisitions and Collaborations

8. Research & Development, 2018

  • 8.1 Prophylactic Vaccines R&D Pipeline
    • 8.1.1 Paediatric Vaccines R&D Pipeline
    • 8.1.2 Adult Vaccines R&D Pipeline
    • 8.1.3 Elderly Vaccines R&D Pipeline
    • 8.1.4 Travel Vaccines R&D Pipeline
  • 8.2 Therapeutic Vaccines R&D Pipeline

9. Qualitative Analysis of the World Vaccines Market

  • 9.1 SWOT Analysis of the World Human Vaccines Market
    • 9.1.1 Strengths
      • 9.1.1.1 Prevention is Better than Cure
      • 9.1.1.2 Demand from Emerging Markets Continue
      • 9.1.1.3 Promising R&D Pipeline
      • 9.1.1.4 Increasing Awareness
    • 9.1.2 Weaknesses
      • 9.1.2.1 High Manufacturing Costs
      • 9.1.2.2 Time Constraints
      • 9.1.2.3 Barriers to Market Entry
    • 9.1.3 Opportunities
      • 9.1.3.1 Constant Improvements in Vaccine Technology and Delivery Methods
      • 9.1.3.2 Shifting Focus on Adults Vaccines
    • 9.1.4 Threats
      • 9.1.4.1 Oligarchic Presence of Pharmaceutical Giants
      • 9.1.4.2 Productivity Gap
  • 9.2 STEP Analysis of the World Human Vaccines Industry and Market
    • 9.2.1 Social Factors
      • 9.2.1.1 Maintaining a Healthier Workforce
      • 9.2.1.2 Public Hesitation - Fear of Unwanted Side-Effects
    • 9.2.2 Technological Forces
      • 9.2.2.1 Evolution of Vaccine Technology Pave the Way for Prophylactics and Therapeutics
    • 9.2.3 Economic Factors
      • 9.2.3.1 High Costs of Production
      • 9.2.3.2 Soaring Vaccines Demand from Developing Countries
    • 9.2.4 Political Factors
      • 9.2.4.1 Governments Play Crucial Roles in Vaccination

10. Conclusions

  • 10.1 Segment Market Share Shift
  • 10.3 Endemic Infections Drive Travel Vaccines Growth
  • 10.4 Emerging Markets: High Demand for Vaccines
  • 10.5 Demand in Mature Pharma Markets Continues: in Particular Japan Will Show Sales Growth
  • 10.6 Strong and Diverse Research and Development
  • 10.7 Concluding Remarks

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 3.1 The Global Top 25 Vaccines Market: Revenue Forecast ($bn), AGR (%), CAGRs (%), 2018-2029
  • Table 5.1 Prevnar Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.2 Gardasil Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.3 Fluzone/Vaxigrip Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.4 Pentacel Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.5 ProQuad Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.6 Infanrix/Pediarix Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.7 Zostavax Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.8 RotaTeq Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.9 GSK Hepatitis Top 25 Vaccines Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.10 Menactra Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.11 Pneumovax 23 Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.12 Varivax Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.13 Bexsero Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.14 Boostrix Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.15 FluMist/Fluenz Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.16 Rotarix Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.17 Synflorix Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.18 FluLaval / Fluarix Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.19 M-M-R II Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.20 Adacel Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.21 Menveo Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.22 Repevax Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.23 Cervarix Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.24 FSME/IMMUN-TicoVac Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.25 Ixiaro Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.1 Leading National Market Revenue Forecasts ($bn), 2018, 2024, 2029
  • Table 6.2 Leading Developed National Markets Revenue Forecasts ($bn), 2018, 2024, 2029
  • Table 6.3 Leading Developed National Market Shares (%), 2018, 2024, 2029
  • Table 6.4 North America Vaccines Revenue Forecast by Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2018-2029
  • Table 6.5 The US Top 25 Vaccines Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.6 Canada Top 25 Vaccines Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.7 Europe Vaccines Revenue Forecast by Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2018-2029
  • Table 6.8 The German Top 25 Vaccines Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.9 The UK Top 25 Vaccines Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.10 France Top 25 Vaccines Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.11 Italy Top 25 Vaccines Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.12 Spain Top 25 Vaccines Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.13 Asia-Pacific Vaccines Revenue Forecast by Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2018-2029
  • Table 6.14 Japan Top 25 Vaccines Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.15 China Top 25 Vaccines Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.16 India Top 25 Vaccines Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.17 RoW Vaccines Revenue Forecast by Leading Vaccines ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.18 Brazil Top 25 Vaccines Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.19 Russia Top 25 Vaccines Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.20 Mexican Top 25 Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2018-2029
  • Table 6.21 South Africa Top 25 Vaccines Revenue Forecast ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 8.1 Prophylactic Vaccines in Development, 2018
  • Table 8.2 Paediatric Vaccines in Development, 2018
  • Table 8.3 Adult Vaccines in Development, 2018
  • Table 8.4 Elderly Vaccines in Development, 2018
  • Table 8.5 Travel Vaccines in Development, 2018
  • Table 8.6 Therapeutic Vaccines in Development, 2018

List of Figures

  • Figure 3.1 Vaccines Market Share within Global Pharmaceutical Market (%), 2018
  • Figure 3.2 Global Top 25 Vaccines Revenue Share Forecast (%) by Leading Vaccine 2018-2029
  • Figure 4.1 World Vaccines Market: Drivers and Restraints
  • Figure 5.1 Prevnar Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.2 Gardasil Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.3 Fluzone/Vaxigrip Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.4 Pentacel Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.5 ProQuad Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.6 Infanrix/Pediarix Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.7 Zostavax Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.8 RotaTeq Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.9 GSK Hepatitis Top 25 Vaccines Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.10 Menactra Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.11 Pneumovax 23 Revenue Forecast ($bn), AGR (%), 2018-2029
  • Figure 5.12 Varivax Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.13 Bexsero Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.14 Boostrix Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.15 FluMist/Fluenz Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.16 Rotarix Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.17 Synflorix Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.18 FluLaval / Fluarix Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.19 M-M-R II Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.20 Adacel Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.21 Menveo Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.22 Repevax Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.23 Cervarix Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.24 FSME/IMMUN-TicoVac Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 5.25 Ixiaro Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 6.1 North America Top 25 Vaccines Market Revenue Share (%) 2018-2029
  • Figure 6.2 The US Top 25 Vaccines Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 6.3 Canada Top 25 Vaccines Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 6.4 Europe Top 25 Vaccines Market Revenue Share (%) 2018-2029
  • Figure 6.5 The German Top 25 Vaccines Revenue Forecast ($bn), 2018-2029
  • Figure 6.6 The UK Top 25 Vaccines Revenue Forecast ($bn), 2018-2029
  • Figure 6.7 The French Top 25 Vaccines Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 6.8 Italian Top 25 Vaccines Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 6.9 Spanish Top 25 Vaccines Revenue Forecast ($bn), 2018-2029
  • Figure 6.10 Asia-Pacific Top 25 Vaccines Market Revenue Share (%) 2018-2029
  • Figure 6.11 Japanese Top 25 Vaccines Revenue Forecast ($bn), 2018-2029
  • Figure 6.12 Chinese Top 25 Vaccines Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 6.13 The Indian Top 25 Vaccines Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 6.14 RoW Top 25 Vaccines Market Revenue Share (%) 2018-2029
  • Figure 6.15 Brazilian Top 25 Vaccines Revenue Forecast ($bn), 2018-2029
  • Figure 6.16 Russian Top 25 Vaccines Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 6.17 Mexican Top 25 Vaccines Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 6.18 South Africa Top 25 Vaccines Revenue Forecast ($bn), AGR (%) 2018-2029
  • Figure 7.1 GSK Vaccines Revenue ($bn), 2015-2017
  • Figure 7.2 GSK Vaccines Region Breakdown (%), 2017
  • Figure 7.3 Merck Vaccines Revenue (%), 2017
  • Figure 7.4 Sanofi Vaccines Revenue ($bn), 2014-2017
  • Figure 7.5 Pfizer Revenue ($bn), 2014-2017
  • Figure 7.6 J&J Revenue ($bn), 2014-2017
  • Figure 7.7 AstraZeneca Revenue ($bn), 2014-2017
  • Figure 7.8 Eli Lilly and Company Revenue ($bn), 2014-2017
  • Figure 7.9 Takeda Pharmaceutical Revenue ($bn), 2014-2017
  • Figure 9.1 SWOT Analysis of the World Vaccines Market
  • Figure 9.2 STEP Analysis of the World Vaccines Market
  • Figure 10.1 World Top 25 Vaccines Revenue Forecast %) by Leading Vaccine 2018-2029
  • Figure 10.2 World Top 25 Vaccines Revenue Forecast %) by Country 2018-2029

List of Organizations Mentioned in the Report:

  • Afferent Pharmaceuticals
  • Allergan
  • AstraZeneca
  • Bavarian Nordic
  • Baxter
  • Bayer
  • Bharat Biotech
  • BiondVax
  • Bristol-Myers Squibb
  • Centre for Biologics Evaluation and Research (CBER)
  • Centre for Disease Control and Prevention (CDC)
  • Chemo-Sero-Therapeutic Research Institute
  • Denka Seiken
  • Developing Countries Vaccine Manufacturers Network (DCVMN)
  • Eli Lilly
  • Emergent BioSolutions Inc.
  • European Medicines Agency (EMA)
  • Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
  • Food and Drug Administration (FDA)
  • GlaxoSmithKline
  • GlaxoWellcome
  • Global Alliance for Vaccines and Immunization (GAVI)
  • Henogen
  • Immatics
  • InnoPharma
  • International Medica Foundation
  • InterveXion Therapeutics
  • Johnson & Johnson
  • MedImmune
  • Merck & Co.
  • Merck Sharp & Dohme Corp
  • NewLink Genetics
  • Novartis
  • Okairos
  • Pan American Health Organization (PAHO)
  • Pfizer
  • Protein Sciences
  • Sanofi Pasteur
  • Serum Indian Institute Pvt. Ltd.
  • Shanghai BravoBio
  • SmithKline Beecham
  • Takeda
  • The US Department of Health and Human Services (HHS)
  • Themis Bioscience
  • UNICEF
  • World Health Organization (WHO)
  • Zymeworks Inc.